Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study
- 8 May 2025
- journal article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 73, 152746
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus ErythematosusJAMA Network Open, 2024
- Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunityCell Metabolism, 2023
- Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney DiseaseCurrent Diabetes Reports, 2022
- Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and DiabetesKidney International Reports, 2021
- Long-Term Cardiovascular Outcomes in Systemic Lupus ErythematosusJACC, 2021
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical StudiesDiabetes Therapy, 2020
- The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic studyAutoimmunity Reviews, 2019
- Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based studyAutoimmunity Reviews, 2014
- Population‐Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance ProgramArthritis & Rheumatology, 2013